
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Med</journal-id><journal-id journal-id-type="iso-abbrev">J. Exp. Med</journal-id><journal-title-group><journal-title>The Journal of Experimental Medicine</journal-title></journal-title-group><issn pub-type="ppub">0022-1007</issn><issn pub-type="epub">1540-9538</issn><publisher><publisher-name>The Rockefeller University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">2193866</article-id><article-id pub-id-type="publisher-id">20021769</article-id><article-id pub-id-type="doi">10.1084/jem.20021769</article-id><article-id pub-id-type="pmid">12591909</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Low Penetrance, Broad Resistance, and Favorable Outcome of Interleukin 12 Receptor β1 Deficiency </plain></SENT>
</text></SecTag></article-title><subtitle>Medical and Immunological Implications</subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fieschi</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dupuis</surname><given-names>Stéphanie</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Catherinot</surname><given-names>Emilie</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Feinberg</surname><given-names>Jacqueline</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bustamante</surname><given-names>Jacinta</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Breiman</surname><given-names>Adrien</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Altare</surname><given-names>Frédéric</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Baretto</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Le Deist</surname><given-names>Françoise</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kayal</surname><given-names>Samer</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Koch</surname><given-names>Hartmut</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Richter</surname><given-names>Darko</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Brezina</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Aksu</surname><given-names>Guzide</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Wood</surname><given-names>Phil</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Al-Jumaah</surname><given-names>Suliman</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Raspall</surname><given-names>Miquel</given-names></name><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>da Silva Duarte</surname><given-names>Alberto José</given-names></name><xref ref-type="aff" rid="aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Tuerlinckx</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Virelizier</surname><given-names>Jean-Louis</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Fischer</surname><given-names>Alain</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Enright</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Bernhöft</surname><given-names>Jutta</given-names></name><xref ref-type="aff" rid="aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Cleary</surname><given-names>Aileen M.</given-names></name><xref ref-type="aff" rid="aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Vermylen</surname><given-names>Christiane</given-names></name><xref ref-type="aff" rid="aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Rodriguez-Gallego</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Davies</surname><given-names>Graham</given-names></name><xref ref-type="aff" rid="aff20">20</xref></contrib><contrib contrib-type="author"><name><surname>Blütters-Sawatzki</surname><given-names>Renate</given-names></name><xref ref-type="aff" rid="aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Siegrist</surname><given-names>Claire-Anne</given-names></name><xref ref-type="aff" rid="aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>Ehlayel</surname><given-names>Mohammad S.</given-names></name><xref ref-type="aff" rid="aff22">22</xref></contrib><contrib contrib-type="author"><name><surname>Novelli</surname><given-names>Vas</given-names></name><xref ref-type="aff" rid="aff20">20</xref></contrib><contrib contrib-type="author"><name><surname>Haas</surname><given-names>Walther H.</given-names></name><xref ref-type="aff" rid="aff23">23</xref><xref ref-type="aff" rid="aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Levy</surname><given-names>Jacob</given-names></name><xref ref-type="aff" rid="aff25">25</xref></contrib><contrib contrib-type="author"><name><surname>Freihorst</surname><given-names>Joachim</given-names></name><xref ref-type="aff" rid="aff26">26</xref></contrib><contrib contrib-type="author"><name><surname>Al-Hajjar</surname><given-names>Sami</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Nadal</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff27">27</xref></contrib><contrib contrib-type="author"><name><surname>de Moraes Vasconcelos</surname><given-names>Dewton</given-names></name><xref ref-type="aff" rid="aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Jeppsson</surname><given-names>Olle</given-names></name><xref ref-type="aff" rid="aff28">28</xref></contrib><contrib contrib-type="author"><name><surname>Kutukculer</surname><given-names>Necil</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Frecerova</surname><given-names>Klara</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Caragol</surname><given-names>Isabel</given-names></name><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Lammas</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kumararatne</surname><given-names>Dinakantha S.</given-names></name><xref ref-type="aff" rid="aff29">29</xref></contrib><contrib contrib-type="author"><name><surname>Abel</surname><given-names>Laurent</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Casanova</surname><given-names>Jean-Laurent</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>Laboratory of Human Genetics of Infectious Diseases, University René Descartes INSERM U550, Necker Medical School</aff><aff id="aff2">
<label>2</label>INSERM U429, Necker Hospital</aff><aff id="aff3">
<label>3</label>INSERM U411, Necker Hospital</aff><aff id="aff4">
<label>4</label>Pediatric Immunology and Hematology Unit, Necker Hospital</aff><aff id="aff5">
<label>5</label>Department of Molecular Medicine, Institut Pasteur, 75015 Paris, France</aff><aff id="aff6">
<label>6</label>MRC Center for Immune Regulation, The Medical School, University of Birmingham, Birmingham B15 2TT, United Kingdom</aff><aff id="aff7">
<label>7</label>Department of Pediatrics, St. Marienhospital, D-49377 Vechta, Germany</aff><aff id="aff8">
<label>8</label>Division of Allergy and Clinical Immunology, Department of Pediatrics, University Hospital Center, 10000 Zagreb, Croatia</aff><aff id="aff9">
<label>9</label>Pediatric Pneumology and Phtiseology Clinic SPAM, National Institute of Tuberculosis and Respiratory Diseases, 82556 Bratislava, Slovak Republic</aff><aff id="aff10">
<label>10</label>Division of Pediatric Immunology, Department of Pediatrics, The Medical School, Ege University, 35100 Izmir, Turkey</aff><aff id="aff11">
<label>11</label>Department of Clinical Chemistry and Immunology, Leeds General Infirmary, Leeds LS1 3EX, United Kingdom</aff><aff id="aff12">
<label>12</label>Department of Pediatrics, King Faycal Hospital and Research Center, 11211 Riyadh, Saudi Arabia</aff><aff id="aff13">
<label>13</label>Pediatric Infectious Diseases Unit and Department of Immunology, Vall d'Hebron Hospital, 08035 Barcelona, Spain</aff><aff id="aff14">
<label>14</label>Primary Immunodeficiency Unit, Department of Dermatology of the Clinical Hospital, and Laboratory of Clinical and Experimental Allergy and Immunology, University of Sao Paulo Medical School, 01246-903 Sao Paulo, Brazil</aff><aff id="aff15">
<label>15</label>Departement of Pediatrics, Catholic University of Louvain at Mont-Godinne, 5530 Yvoir, Belgium</aff><aff id="aff16">
<label>16</label>Department of Pediatrics, Stanford University Medical Center, Stanford, CA 94010</aff><aff id="aff17">
<label>17</label>Department of Pediatric Hematology and Oncology, D35385 Giessen, Germany</aff><aff id="aff18">
<label>18</label>Department of Pediatric Hematology, Cliniques Universitaires Saint Luc, Louvain Medical School, B-1200 Brussels, Belgium</aff><aff id="aff19">
<label>19</label>Department of Immunology, Gran Canaria Dr Negrin Hospital, 35020 Las Palmas, Spain</aff><aff id="aff20">
<label>20</label>Division of Paediatric Infectious Diseases, Great Ormond Street Children's Hospital, London WC1N 3JH, United Kingdom</aff><aff id="aff21">
<label>21</label>Department of Pediatrics, University Hospital of Geneva, 1211, Geneva 4, Switzerland</aff><aff id="aff22">
<label>22</label>Hamad Medical Corporation, P.O. Box: 3050, Doha, Qatar</aff><aff id="aff23">
<label>23</label>Department of General Pediatrics, Children's Hospital, University of Heidelberg, D-69120 Heidelberg, Germany</aff><aff id="aff24">
<label>24</label>Center for Epidemiology of Infectious Diseases, Robert Koch Institute, D-10963 Berlin, Germany</aff><aff id="aff25">
<label>25</label>Division of Pediatrics, Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University, Beer Sheva 84101, Israel</aff><aff id="aff26">
<label>26</label>Pediatric Pulmonology and Neonatology, Hannover Medical School, D-30623 Hannover, Germany</aff><aff id="aff27">
<label>27</label>Division of Infectious Diseases, University Children's Hospital of Zürich, CH-8032 Zürich, Switzerland</aff><aff id="aff28">
<label>28</label>Children's Hospital, Huddinge University Hospital, 141 86 Huddinge, Sweden</aff><aff id="aff29">
<label>29</label>Departments of Clinical Immunology and Medicine, Addenbrookes Hospital NHS Trust, Hill Road, Cambridge CB2 2QQ, United Kingdom</aff><author-notes><fn><p><text><SENT sid="1" pm="."><plain>Address correspondence to Jean-Laurent Casanova, Laboratoire de Génétique Humaine des Maladies Infectieuses, Université René Descartes-INSERM U550, Faculté de Médecine Necker, 156 rue de Vaugirard, 75015 Paris, France. </plain></SENT>
<SENT sid="2" pm="."><plain>Phone: 33-1-40-61-56-87; Fax: 33-1-40-61-56-88; E-mail: casanova@necker.fr </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><day>17</day><month>2</month><year>2003</year></pub-date><volume>197</volume><issue>4</issue><fpage>527</fpage><lpage>535</lpage><history><date date-type="received"><day>7</day><month>10</month><year>2002</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2003</year></date></history><permissions><copyright-statement>Copyright © 2003, The Rockefeller University Press</copyright-statement><license license-type="openaccess"><license-p>This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see <ext-link ext-link-type="uri" xlink:href="http://www.rupress.org/terms">http://www.rupress.org/terms</ext-link>). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link>).</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="3" pm="."><plain>The clinical phenotype of interleukin 12 receptor β1 chain (IL-12Rβ1) deficiency and the function of human IL-12 in host defense remain largely unknown, due to the small number of patients reported. </plain></SENT>
<SENT sid="4" pm="."><plain>We now report 41 patients with complete IL-12Rβ1 deficiency from 17 countries. </plain></SENT>
<SENT sid="5" pm="."><plain>The only opportunistic infections observed, in 34 patients, were of childhood onset and caused by weakly virulent Salmonella or Mycobacteria (Bacille Calmette-Guérin -BCG- and environmental Mycobacteria). </plain></SENT>
<SENT sid="6" pm="."><plain>Three patients had clinical tuberculosis, one of whom also had salmonellosis. </plain></SENT>
<SENT sid="7" pm="."><plain>Unlike salmonellosis, mycobacterial infections did not recur. </plain></SENT>
<SENT sid="8" pm="."><plain>BCG inoculation and BCG disease were both effective against subsequent environmental mycobacteriosis, but not against salmonellosis. </plain></SENT>
<SENT sid="9" pm="."><plain>Excluding the probands, seven of the 12 affected siblings have remained free of case-definition opportunistic infection. </plain></SENT>
<SENT sid="10" pm="."><plain>Finally, only five deaths occurred in childhood, and the remaining 36 patients are alive and well. </plain></SENT>
<SENT sid="11" pm="."><plain>Thus, a diagnosis of IL-12Rβ1 deficiency should be considered in children with opportunistic mycobacteriosis or salmonellosis; healthy siblings of probands and selected cases of tuberculosis should also be investigated. </plain></SENT>
<SENT sid="12" pm="."><plain>The overall prognosis is good due to broad resistance to infection and the low penetrance and favorable outcome of infections. </plain></SENT>
<SENT sid="13" pm="."><plain>Unexpectedly, human IL-12 is redundant in protective immunity against most microorganisms other than Mycobacteria and Salmonella. </plain></SENT>
<SENT sid="14" pm="."><plain>Moreover, IL-12 is redundant for primary immunity to Mycobacteria and Salmonella in many individuals and for secondary immunity to Mycobacteria but not to Salmonella in most. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd><italic>Mycobacteria</italic></kwd><kwd><italic>Salmonella</italic></kwd><kwd>immunodeficiency</kwd><kwd>interleukin 12 receptor</kwd><kwd>interferon γ</kwd></kwd-group></SecTag></article-meta><notes><fn-group><fn><p><text><SENT sid="15" pm="."><plain>F. </plain></SENT>
<SENT sid="16" pm="."><plain>Altare's present address is Institute of Pharmacology and Structural Biology, CNRS UMR 5089, 31077 Toulouse, France. </plain></SENT>
</text></p></fn></fn-group></notes></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="17" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="18" pm="."><plain>Mendelian susceptibility to mycobacterial disease (MSMD; Mendelian inheritance in man [MIM] 209950) (1) is a rare syndrome which results in predisposition to clinical disease caused by poorly virulent mycobacterial species such as the Bacillus Calmette-Guérin (BCG)* vaccines (2) and nontuberculous environmental Mycobacteria (EM; reference 3). </plain></SENT>
<SENT sid="19" pm="."><plain>Patients are also susceptible to virulent Mycobacterium tuberculosis (1). </plain></SENT>
<SENT sid="20" pm="."><plain>Unlike patients with classic immunodeficiencies, these patients rarely present other unusual infectious diseases, with the exception of extra-intestinal nontyphoid salmonellosis, which affects less than half of them. </plain></SENT>
<SENT sid="21" pm="."><plain>Histopathological and clinical heterogeneity are suggestive of genetic heterogeneity. </plain></SENT>
<SENT sid="22" pm="."><plain>Some sporadic and most familial cases suggest autosomal recessive heredity, but the syndrome segregates in an autosomal dominant (4) or X-linked recessive (5) pattern in some families. </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>Five disease-causing autosomal genes have been found, and allelic heterogeneity accounts for the existence of nine defined disorders, all of which result in impaired IFN-γ–mediated immunity (1). </plain></SENT>
<SENT sid="24" pm="."><plain>Null recessive mutations in the IFN-γ-receptor ligand-binding chain (IFN-γR1)-encoding gene (IFNGR1) abolish either receptor expression (6, 7) or the binding of surface-expressed receptors to IFN-γ (8). </plain></SENT>
<SENT sid="25" pm="."><plain>Partial recessive (9) and dominant (4) IFN-γR1 deficiencies have also been described. </plain></SENT>
<SENT sid="26" pm="."><plain>Different recessive mutations in the gene of the IFN-γ signaling chain (IFN-γR2), IFNGR2, are responsible for complete (10) or partial (11) IFN-γR2 deficiency. </plain></SENT>
<SENT sid="27" pm="."><plain>A dominant mutation in STAT1, resulting in partial STAT-1 (signal transducer and activator of transcription-1) deficiency and impaired cellular responses to IFN-γ, has also been identified in other kindreds (12). </plain></SENT>
</text></p><p><text><SENT sid="28" pm="."><plain>The remaining two genetic defects result in normal cellular responses to IFN-γ, but abnormal IL-12–dependent production of IFN-γ. </plain></SENT>
<SENT sid="29" pm="."><plain>A few children are homozygous for null mutations in IL12B, encoding the p40 subunit of IL-12 (13–15). </plain></SENT>
<SENT sid="30" pm="."><plain>Null recessive IL12RB1 mutations have been identified in other patients with IL-12 receptor β1 chain deficiency (15–21). </plain></SENT>
<SENT sid="31" pm="."><plain>These studies (13–21) only addressed case reports or small cohorts of patients, making it difficult to estimate the range of pathogenic microorganisms and the severity of the clinical course. </plain></SENT>
<SENT sid="32" pm="."><plain>These issues are of both clinical and immunological importance, given the central role attributed to IL-12 in Th1 development and immunity to various pathogens (22–24). </plain></SENT>
<SENT sid="33" pm="."><plain>Here, we describe the IL12RB1 genotype and the cellular and clinical phenotypes of 41 patients with IL-12Rβ1 deficiency. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods"><title><text><SENT sid="34" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec><title><text><SENT sid="35" pm="."><plain>Subjects, Kindreds, and Statistical Methods. </plain></SENT>
</text></title><p><text><SENT sid="36" pm="."><plain>We investigated 120 unrelated patients, including five previously described patients (16, 19, 20). </plain></SENT>
<SENT sid="37" pm="."><plain>Our study was conducted according to the principles expressed in the Helsinki Declaration, with informed consent obtained from each patient or the patient's family. </plain></SENT>
<SENT sid="38" pm="."><plain>The proportion of infection-free individuals, survival, and penetrance were calculated by the Kaplan-Meier method, and the differences between curves were assessed by the log-rank test. </plain></SENT>
<SENT sid="39" pm="."><plain>All calculations were performed with the Lifetest procedure of SAS version 8.2 (SAS). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="40" pm="."><plain>Cell Culture and Stimulation. </plain></SENT>
</text></title><p><text><SENT sid="41" pm="."><plain>Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-B cell lines) were cultured as described previously (14). </plain></SENT>
<SENT sid="42" pm="."><plain>Whole blood samples were diluted 1:2 in RPMI 1640 (Invitrogen) and infected by incubation with live M. bovis BCG at a multiplicity of infection of 20:1, alone or with recombinant IL-12p70 (20 ng/ml; R&amp;D Systems), for 48 h. </plain></SENT>
<SENT sid="43" pm="."><plain>Alternatively, PBMCs were cultured in RPMI 1640 supplemented with 10% heat-inactivated pooled human AB serum, and activated by incubation with PHA P 1/700 (Bacto PHA-P; Becton Dickinson) for 72 h. </plain></SENT>
<SENT sid="44" pm="."><plain>T cell blasts were restimulated every 48 h with IL-2 (40 IU/ml; Chiron Corp.). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="45" pm="."><plain>ELISA and Flow Cytometry. </plain></SENT>
</text></title><p><text><SENT sid="46" pm="."><plain>Cell culture supernatants were assayed for IFN-γ by ELISA, according to the kit manufacturer's recommendations (Pelikin Compact, CLB). </plain></SENT>
<SENT sid="47" pm="."><plain>IFN-γ concentration was calculated per 1 million PBMCs. </plain></SENT>
<SENT sid="48" pm="."><plain>T cell blasts and/or EBV-B cells were first incubated with an IL-12Rβ1–specific mouse IgG1 mAb (24E6), an IL-12Rβ1–specific rat IgG2a mAb (2B10), or isotypic control mAbs, then with a biotinylated rat anti–mouse Ab or a biotinylated mouse anti–rat Ab, and finally with streptavidin-PE (all reagents were obtained from BD Biosciences/Becton Dickinson). </plain></SENT>
<SENT sid="49" pm="."><plain>Signals were analyzed with a FACScan™ machine, using CELLQuest™ software (Becton Dickinson). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="50" pm="."><plain>DNA and RNA Extraction, cDNA Synthesis, and PCR Amplification. </plain></SENT>
</text></title><p><text><SENT sid="51" pm="."><plain>Genomic DNA and total RNA were extracted from EBV-transformed B cells or T cell blasts, as described previously (14). </plain></SENT>
<SENT sid="52" pm="."><plain>RNA was reverse transcribed in the presence of oligo (dT) with Superscript II reverse transcriptase (Invitrogen; reference 14). </plain></SENT>
<SENT sid="53" pm="."><plain>The IL12RB1 cDNA, coding exons and flanking intron regions were amplified using pairs of primers and PCR conditions available upon request. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="54" pm="."><plain>Single-stranded Chain Polymorphism and Sequencing. </plain></SENT>
</text></title><p><text><SENT sid="55" pm="."><plain>Single-stranded chain polymorphism (SSCP) analysis and PCR were performed with pairs of intron primers flanking each IL12RB1 exon, under conditions available upon request. </plain></SENT>
<SENT sid="56" pm="."><plain>PCR products were sequenced by dideoxynucleotide termination with nested primers (available upon request) and the BigDye terminator kit. </plain></SENT>
<SENT sid="57" pm="."><plain>PCR products were sequenced on an ABI Prism 3100 apparatus, and analyzed with Sequencing Analysis software (Applied Biosystems). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec><title><text><SENT sid="58" pm="."><plain>Results </plain></SENT>
</text></title><p><text><SENT sid="59" pm="."><plain>We investigated 120 unrelated probands, including 100 with MSMD syndrome (disseminated BCG or EM disease with or without salmonellosis), and 20 with only nontyphoid extraintestinal salmonellosis, as we recently described a child with salmonellosis as the sole infectious disease and IL-12p40 deficiency (14). </plain></SENT>
</text></p><sec><title><text><SENT sid="60" pm="."><plain>Detection of IL12RB1 Mutations and Intrafamilial Segregation. </plain></SENT>
</text></title><p><text><SENT sid="61" pm="."><plain>The 17 IL12RB1 coding exons and flanking intron regions were analyzed by SSCP. </plain></SENT>
<SENT sid="62" pm="."><plain>25 patients displayed a unique SSCP pattern, each for only one exon (Kindreds 1–9, 11–16, 18-26, 29; Table I and Fig. 1) . </plain></SENT>
<SENT sid="63" pm="."><plain>Three additional patients (17.II.2, 27.II.2, 28.II.3) displayed unique SSCP patterns for two separate exons, and in one patient (10.II.2), exons 8 to 13 were not amplified. </plain></SENT>
<SENT sid="64" pm="."><plain>All coding exons were sequenced in these 29 patients with abnormal SSCP patterns. </plain></SENT>
<SENT sid="65" pm="."><plain>Introns 7 and 13 were also sequenced in patient 10.II.2, and introns 12 and 13 in patient 19.II.1 (owing to the identification of a cDNA of low molecular weight, see below). </plain></SENT>
<SENT sid="66" pm="."><plain>The patients were found to be homozygous, or compound heterozygous for nonsense (n = 4), splice (n = 4), and missense (n = 6) mutations, small insertions (n = 1), large deletions (n = 2), and deletions/insertions (n = 4; a total of 21 mutant alleles; Table I). </plain></SENT>
<SENT sid="67" pm="."><plain>None of the mutations were found in 50 unrelated healthy individuals from the corresponding ethnic group. </plain></SENT>
<SENT sid="68" pm="."><plain>We then amplified and sequenced the full-length IL12RB1 cDNA coding region for the 29 probands. IL12RB1 transcripts of low molecular weight were found in patients 10.II.2 and 19.II.1. </plain></SENT>
<SENT sid="69" pm="."><plain>In patients homozygous for splice mutations, no full-length mRNAs were found. </plain></SENT>
<SENT sid="70" pm="."><plain>All parents tested were heterozygous for one IL12RB1 mutation. </plain></SENT>
<SENT sid="71" pm="."><plain>Only 12 of the 61 known siblings could not be genotyped (designated “E?” in Fig. 1). </plain></SENT>
<SENT sid="72" pm="."><plain>Two had died of proven BCG (26.II.1) or EM (4.II.2) infection and therefore probably carried the disease-associated IL12RB1 genotype. </plain></SENT>
<SENT sid="73" pm="."><plain>10 of the 49 siblings tested, from nine kindreds, carried two mutant IL12RB1 alleles, raising the number of affected siblings to 12. </plain></SENT>
<SENT sid="74" pm="."><plain>Altogether, we report 41 individuals from 29 kindreds demonstrated (n = 39) or thought (n = 2) to be homozygous or compound heterozygous for IL12RB1 mutations, including 29 probands and 12 siblings. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="tbl1" position="float"><label>Table I.</label><caption><p><text><SENT sid="75" pm="."><plain>Genotypes and Clinical Phenotypes of Patients with IL-12 Receptor β1 Deficiency </plain></SENT>
</text></p></caption><table-wrap-foot><fn id="tfn1"><label>a</label><p><text><SENT sid="76" pm="."><plain>Children 3.II.2, 5.II.1, 6.II.1, 7.II.1 and 9.II.2 (Fig. 1) died during their first year of life of unknown causes; they were not available for genetic analysis (no DNA available), and thus were not included in the present series of patients as their phenotype and genotype were unclear. </plain></SENT>
<SENT sid="77" pm="."><plain>In contrast, two patients with the known phenotype of BCG and/or EM infection were included despite their genotype not being known (4.II.2 and 26.II.1). </plain></SENT>
</text></p></fn><fn id="tfn2"><label>b</label><p><text><SENT sid="78" pm="."><plain>Mutation nomenclature follows the recommendations of Antonarakis and den Dunnen (reference 52). </plain></SENT>
<SENT sid="79" pm="."><plain>Mutation Q214R initially found in patient 4.II.1 (16), was subsequently found to be a polymorphism. “Delins” indicates mutations combining the deletion and insertion of nucleotides. </plain></SENT>
</text></p></fn><fn id="tfn3"><label>c</label><p><text><SENT sid="80" pm="."><plain>The clinical features of kindreds 1, 4, and 5 were initially reported in 1998 (reference 16), kindred 2 in 2001 (reference 20), kindred 4 in 1995 (reference 3) and 2000 (reference 18), kindred 5 in 1988 (reference 53), kindred 7 in 2001 (reference 19), and kindred 21 in 1997 (reference 54). </plain></SENT>
<SENT sid="81" pm="."><plain>The countries of residence in some cases differ from the countries of origin: kindred 1 lives in France, kindreds 4 and 15 live in the United Kingdom, kindreds 5 and 6 living in Sweden and originating from Turkey are of the Kurd ethnic group, kindred 9 originating from Turkey lives in Germany, kindred 10 originating from and living in Israel is of the Bedouin ethnic group, kindred 14 lives in USA, kindred 16 lives in Switzerland. </plain></SENT>
</text></p></fn><fn id="tfn4"><label>d</label><p><text><SENT sid="82" pm="."><plain>Deceased or alive. </plain></SENT>
</text></p></fn><fn id="tfn5"><label>e</label><p><text><SENT sid="83" pm="."><plain>Age at death or at the time of writing this report. </plain></SENT>
</text></p></fn><fn id="tfn6"><label>f</label><p><text><SENT sid="84" pm="."><plain>BCG, Bacille Calmette-Guérin; D, Disseminated; EM, Environmental Mycobacteria; Mtb, Mycobacterium tuberculosis; nv, not vaccinated with BCG; Resistant, no adverse reaction to BCG vaccination; M. spp, patient 26.II.4 was not BCG-vaccinated and suffered from chronic disseminated granulomatous disease that responded to empirical anti-mycobacterial treatment (rifampicin, isoniazid, ethambutol, amikacin); no mycobacterial species were visible or cultured, suggesting atypical mycobacteriosis. </plain></SENT>
<SENT sid="85" pm="."><plain>Patient 10.II.2 also had Kingella kingae infections, and patient 29.II.1 Paracoccidioides brasiliensis infections. </plain></SENT>
<SENT sid="86" pm="."><plain>Patient 4.II.1, previously reported not to have been vaccinated (references 3, 16, and 18), had in fact been inoculated with BCG at 5 yr of age. </plain></SENT>
<SENT sid="87" pm="."><plain>Sera from 26, 25, and 22 patients were tested for Ab against non-typhoid Salmonella, Toxoplasma gondii, and cytomegalovirus, respectively. </plain></SENT>
<SENT sid="88" pm="."><plain>The detailed clinical features of all patients will be reported elsewhere. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="FIG"><fig id="fig1" position="float"><label>Figure 1.</label><caption><p><text><SENT sid="89" pm="."><plain>Pedigrees of 29 kindreds with IL-12 receptor β1 deficiency. </plain></SENT>
<SENT sid="90" pm="."><plain>Each kindred is designated by a capital letter (1–29), each generation by a roman numeral (I–II), and each individual by an Arabic numeral (from left to right). </plain></SENT>
<SENT sid="91" pm="."><plain>Symbols are partitioned in two parts by a horizontal line: the upper part indicates infections with Mycobacteria (in black, patients with BCGosis or atypical mycobacteriosis; in gray, patients with tuberculosis); the lower part indicates infections with Salmonella (in black, nontyphoid salmonellosis). </plain></SENT>
<SENT sid="92" pm="."><plain>The proband are indicated by an arrow. </plain></SENT>
<SENT sid="93" pm="."><plain>Individuals whose genetic status could not be evaluated are indicated by the symbol “E?”. </plain></SENT>
<SENT sid="94" pm="."><plain>Asymptomatic individuals carrying two mutant IL12RB1 alleles are represented by a vertical line. </plain></SENT>
</text></p></caption><graphic xlink:href="20021769f1"/></fig></SecTag></sec><sec><title><text><SENT sid="95" pm="."><plain>Impaired Surface Expression and Function of IL-12Rβ1. </plain></SENT>
</text></title><p><text><SENT sid="96" pm="."><plain>We assessed IL-12Rβ1 expression on the surface of T cell blasts (kindreds 9, 14, 15, 22, 25), EBV-transformed B cells (kindreds 8, 11, 19, 20, 29), or both (kindreds 3, 6, 10, 12, 16, 17, 23, 24, 26–28), from 21 of the 24 newly diagnosed probands, by flow cytometry with specific antibodies. </plain></SENT>
<SENT sid="97" pm="."><plain>Consistent with the five patients previously reported (16, 19, 20), no IL-12Rβ1 molecules were detected on the surface of cells from all but one patient. </plain></SENT>
<SENT sid="98" pm="."><plain>Patient 10.II.2, carrying a large in-frame deletion, presented an expression of the β1 chain, both on T cell blasts and EBV-transformed B cells, detectable with one monoclonal antibody (24E6), but not with another (2B10; data not depicted). </plain></SENT>
<SENT sid="99" pm="."><plain>Cells from the three remaining probands (kindreds 13, 18, 21) were not tested for IL-12Rβ1 expression, but were homozygous for mutations found in other kindreds (Table I). </plain></SENT>
<SENT sid="100" pm="."><plain>The cells from all 21 patients tested, including the proband from kindred 10 with residual IL-12Rβ1 expression produced less IFN-γ than the “travel” and “local” laboratory controls in response to BCG (mean of 76 versus 664 and 4,109 pg/ml), and production was not increased by IL-12 (mean of 87 versus 22,432 and 65,636 pg/ml; Fig. 2) . </plain></SENT>
<SENT sid="101" pm="."><plain>Some patients were not tested with this assay (kindreds 4, 7, 12, 13, 14, 18, 22, 29). </plain></SENT>
<SENT sid="102" pm="."><plain>However, kindreds 4, 7, 14, 18, and 22 carry the same mutation as other patients (Table I). </plain></SENT>
<SENT sid="103" pm="."><plain>We and others have demonstrated that T cells homozygous for the IL12RB1 missense mutation R213W (kindred 2) are complemented by transfection with a wild-type IL12RB1 allele (20, 21). </plain></SENT>
<SENT sid="104" pm="."><plain>Overall, we have demonstrated complete IL-12Rβ1 deficiency in 29 patients (absence of detectable IL-12Rβ1 surface expression, n = 28, absence of response to IL-12, n = 27, or both, n = 27). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig2" position="float"><label>Figure 2.</label><caption><p><text><SENT sid="105" pm="."><plain>Impaired cellular response to interleukin-12. </plain></SENT>
<SENT sid="106" pm="."><plain>Production of IFN-γ by whole blood cells from 20 healthy “local” positive controls (fresh blood), from 16 healthy “travel” positive controls and from 21 patients, either unstimulated (−) or stimulated with BCG alone or with BCG plus recombinant IL-12p70. </plain></SENT>
<SENT sid="107" pm="."><plain>Fresh, heparinized blood from 7 patients and all “travel” controls were shipped to Paris within 12 to 48 h, where the experiments were performed. </plain></SENT>
<SENT sid="108" pm="."><plain>Blood from four patients and all “local” control was drawn in Paris and readily stimulated. </plain></SENT>
<SENT sid="109" pm="."><plain>The supernatants were harvested after 48 h of activation for cytokine quantification by ELISA. </plain></SENT>
<SENT sid="110" pm="."><plain>The horizontal bars represent the arithmetic mean of the values. </plain></SENT>
</text></p></caption><graphic xlink:href="20021769f2"/></fig></SecTag></sec><sec><title><text><SENT sid="111" pm="."><plain>Onset and Outcome of Infections in IL-12Rβ1–deficient Patients. </plain></SENT>
</text></title><p><text><SENT sid="112" pm="."><plain>We first analyzed the 34 individuals who developed case-definition opportunistic infections caused by weakly virulent microorganisms (BCG, EM, and nontyphoid Salmonella; Table I). </plain></SENT>
<SENT sid="113" pm="."><plain>25 of these 34 patients had been inoculated with live BCG in childhood. </plain></SENT>
<SENT sid="114" pm="."><plain>Only 18 developed disseminated BCG disease, within six months of inoculation (Fig. 3 a). </plain></SENT>
<SENT sid="115" pm="."><plain>No recurrence of BCG disease was observed in the 16 patients who survived the initial BCG infection. </plain></SENT>
<SENT sid="116" pm="."><plain>Eight patients suffered EM disease. </plain></SENT>
<SENT sid="117" pm="."><plain>EM disease began before the age of six years, in all but two patients (4.II.1 and 7.II.5) who developed M. avium and M. fortuitum infections at the ages of 17 and 10 yr, respectively. </plain></SENT>
<SENT sid="118" pm="."><plain>One of these two patients (4.II.1), unlike the others, suffered a second EM disease, caused by M. triplex. </plain></SENT>
<SENT sid="119" pm="."><plain>Finally, disseminated nontyphoid salmonellosis occurred in 21 of 34 patients. </plain></SENT>
<SENT sid="120" pm="."><plain>Salmonellosis was the only infectious disease for seven patients. </plain></SENT>
<SENT sid="121" pm="."><plain>First Salmonella infection occurred at or before the age of 12 yr. </plain></SENT>
<SENT sid="122" pm="."><plain>Eight patients had recurrent salmonellosis (8/21, 38%), involving the same serotype, whereas BCG and EM infections were not recurrent. </plain></SENT>
<SENT sid="123" pm="."><plain>Nevertheless, we found high titers of Salmonella-specific antibodies in the sera of 4 deficient patients with no history of clinical salmonellosis. </plain></SENT>
<SENT sid="124" pm="."><plain>Only five of the 34 infected IL-12Rβ1-deficient patients died due to BCG (n = 2) or EM (n = 3; a mortality rate among symptomatic patients of only 15% [5/34]) (Fig. 3 b). </plain></SENT>
<SENT sid="125" pm="."><plain>All deaths occurred before 8 yr of age. </plain></SENT>
<SENT sid="126" pm="."><plain>No death was attributable to salmonellosis. </plain></SENT>
<SENT sid="127" pm="."><plain>Thus, infections caused by weakly virulent Mycobacteria and Salmonella in IL12Rβ1-deficient patients generally have a childhood onset and a favorable clinical outcome, particularly once patients have entered their teens. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig3" position="float"><label>Figure 3.</label><caption><p><text><SENT sid="128" pm="."><plain>Epidemiological features of IL-12Rβ1 deficiency. </plain></SENT>
<SENT sid="129" pm="."><plain>First onset (a) and outcome (b) of case-definition opportunistic infectious diseases in 34 deficient patients, according to infections: BCG (broken black line), EM (broken gray line), Salmonella (solid gray line), and all 3 infections (solid black line). </plain></SENT>
<SENT sid="130" pm="."><plain>(c) Penetrance of case-definition infectious diseases in the 12 IL-12Rβ1–deficient siblings (excluding all probands). </plain></SENT>
<SENT sid="131" pm="."><plain>(d) Variations in onset of EM disease among the 41 deficient patients, who had been vaccinated with BCG and suffered BCG disease (broken black line, n = 18), who had been vaccinated with BCG without developing BCG disease (resistance to BCG, solid black line, n = 9), or who had not been vaccinated with BCG (solid gray line, n = 14). </plain></SENT>
</text></p></caption><graphic xlink:href="20021769f3"/></fig></SecTag></sec><sec><title><text><SENT sid="132" pm="."><plain>Clinical Penetrance and Impact of BCG on Clinical Phenotype. </plain></SENT>
</text></title><p><text><SENT sid="133" pm="."><plain>We determined the clinical penetrance of IL12Rβ1 deficiency, by excluding all probands (Fig. 3 c). </plain></SENT>
<SENT sid="134" pm="."><plain>Five (42%) of the 12 affected siblings were completely free of unusual infections at their last follow-up visit (mean duration of follow-up: 13.8 yr, range: 7–18 yr). </plain></SENT>
<SENT sid="135" pm="."><plain>None of the other 7 siblings had more than one infection. </plain></SENT>
<SENT sid="136" pm="."><plain>Two of the six siblings who had been vaccinated had disseminated BCG disease. </plain></SENT>
<SENT sid="137" pm="."><plain>Three additional siblings developed infections with weakly virulent microorganisms, EM in one case and Salmonella in the other two. </plain></SENT>
<SENT sid="138" pm="."><plain>Overall, the penetrance of opportunistic infections was estimated to be 45.3% (confidence interval [CI] 95%: 14.2%-75.4%) when calculated with survival analysis techniques to account for differences in follow-up period (Fig. 3 c). </plain></SENT>
<SENT sid="139" pm="."><plain>Finally, tuberculosis occurred in 2 other siblings (2.II.1, 24.II.3). </plain></SENT>
<SENT sid="140" pm="."><plain>We then determined the impact of BCG on the clinical phenotype for the 41 patients described herein. </plain></SENT>
<SENT sid="141" pm="."><plain>BCG inoculation or disease had no impact on the occurrence (and age at onset) of Salmonella infection, or the occurrence of tuberculosis. </plain></SENT>
<SENT sid="142" pm="."><plain>In contrast, none of the 18 patients with BCG disease developed EM disease (interval between onset of BCG disease and last follow-up: 3–31 yr, mean 12.8 yr). </plain></SENT>
<SENT sid="143" pm="."><plain>Only two (4.II.1 and 7.II.5) of the nine patients resistant to BCG (BCG inoculation without BCG disease) suffered EM disease, with late onset of the disease. </plain></SENT>
<SENT sid="144" pm="."><plain>Six (43%) of the 14 patients who had not been inoculated with BCG suffered EM disease (Fig. 3 d), with early onset of the disease. </plain></SENT>
<SENT sid="145" pm="."><plain>The difference in age at onset of EM disease between the three groups of patients was highly significant (P &lt; 0.004; Fig. 3 d). </plain></SENT>
<SENT sid="146" pm="."><plain>This difference was particularly clear if patients with BCG disease were compared with patients not inoculated with BCG (P &lt; 0.004). </plain></SENT>
<SENT sid="147" pm="."><plain>The difference between patients resistant to BCG and nonvaccinated patients was not significant (P = 0.09). </plain></SENT>
<SENT sid="148" pm="."><plain>Finally, the difference in incidence of EM disease between BCG-inoculated patients (with or without BCG disease) and nonvaccinated patients was highly significant (P &lt; 0.002). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec><title><text><SENT sid="149" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="150" pm="."><plain>We report here the first large series of patients with complete IL-12Rβ1 deficiency, including 41 deficient individuals from 29 unrelated kindreds (Table I and Fig. 1). </plain></SENT>
<SENT sid="151" pm="."><plain>The kindreds originate from 17 countries, in Africa, America, Asia, and Europe. </plain></SENT>
<SENT sid="152" pm="."><plain>Seven other unrelated patients reported elsewhere (15, 17, 18, 21) raise the total number of cases to 48, from 36 kindreds, in 20 countries. </plain></SENT>
<SENT sid="153" pm="."><plain>The cellular phenotype of IL-12-receptor β1 chain–deficient patients is uniform: all patients tested failed to respond to IL-12. </plain></SENT>
<SENT sid="154" pm="."><plain>The relative contributions to the clinical phenotype of the lack of response of NK cells (16) and of T lymphocytes (15–18, 21) to IL-12 are unclear. </plain></SENT>
<SENT sid="155" pm="."><plain>The receptor for IL-23, another IFN-γ–inducing cytokine, contains the IL-12Rβ1 subunit (25), suggesting that patients with IL-12Rβ1 deficiency probably also suffer from IL-23 receptor deficiency. </plain></SENT>
</text></p><p><text><SENT sid="156" pm="."><plain>The results obtained in this study confirm that IL-12Rβ1 deficiency is principally associated with mycobacterial diseases (Table I). </plain></SENT>
<SENT sid="157" pm="."><plain>If we include the seven patients reported elsewhere (15, 17, 18, 21), 33 of the 48 patients have had BCG (n = 22) or EM (n = 11) disease. </plain></SENT>
<SENT sid="158" pm="."><plain>We also report three patients from two kindreds with M. tuberculosis disease. </plain></SENT>
<SENT sid="159" pm="."><plain>Thus, a diagnosis of IL-12 receptor deficiency should be considered in patients with unusually severe forms of tuberculosis (20). </plain></SENT>
<SENT sid="160" pm="."><plain>Mice with a disrupted IL12B gene (26) are susceptible to BCG (27), M. tuberculosis (27–29) and, to a lesser extent, to M. avium (30–32). </plain></SENT>
<SENT sid="161" pm="."><plain>Our results extend these observations, and highlight the crucial role of IL-12 in immunity to BCG, several EM and M. tuberculosis in humans. </plain></SENT>
</text></p><p><text><SENT sid="162" pm="."><plain>However, IL-12Rβ1–deficient patients are less susceptible to Mycobacteria than was initially thought (15–21). </plain></SENT>
<SENT sid="163" pm="."><plain>9 of 27 children inoculated with BCG did not suffer adverse effects. </plain></SENT>
<SENT sid="164" pm="."><plain>Only 8 of the 41 patients (19%) in this series, and 11 of the 48 (23%) including the cases reported elsewhere (17, 18, 21), developed EM infections. </plain></SENT>
<SENT sid="165" pm="."><plain>Excluding the probands, only 2 of 6 siblings vaccinated with BCG and 1 of 12 IL-12Rβ1–deficient siblings developed BCG and EM disease, respectively. </plain></SENT>
<SENT sid="166" pm="."><plain>Paradoxically, these data indicate that most IL-12Rβ1–deficient patients do not have the original phenotype of BCG/EM disease or salmonellosis. </plain></SENT>
<SENT sid="167" pm="."><plain>Healthy siblings of probands should therefore be investigated. </plain></SENT>
<SENT sid="168" pm="."><plain>IL-12 is surprisingly redundant in protective immunity against primary infection by weakly virulent Mycobacteria in a majority of individuals. </plain></SENT>
</text></p><p><text><SENT sid="169" pm="."><plain>In our survey, the age at onset of EM disease differed between patients with and without BCG disease. </plain></SENT>
<SENT sid="170" pm="."><plain>If we include the other IL-12Rβ1– and IL-12p40–deficient cases (13–15, 17, 18, 21), there are 63 patients in total, 36 of whom had BCG disease. </plain></SENT>
<SENT sid="171" pm="."><plain>None of these 36 patients developed EM disease, while among the 27 patients who did not develop any BCG disease 12 developed EM disease (P &lt; 10−6, Fisher's exact test). </plain></SENT>
<SENT sid="172" pm="."><plain>This indicates that BCG disease protects against subsequent EM illness in patients with IL-12 deficiency or IL-12R deficiency. </plain></SENT>
<SENT sid="173" pm="."><plain>Antibiotic treatment against BCG probably played a minor role in preventing EM disease, as it was discontinued after a few years in all patients. </plain></SENT>
<SENT sid="174" pm="."><plain>Moreover, the impact of BCG inoculation itself (with or without BCG disease) was also significant in our series. </plain></SENT>
<SENT sid="175" pm="."><plain>Similarly, EM disease was protective in itself. </plain></SENT>
<SENT sid="176" pm="."><plain>In contrast, BCG inoculation and EM disease had no effect on the incidence of salmonellosis. </plain></SENT>
<SENT sid="177" pm="."><plain>IL-12 is thus redundant for adaptive, secondary immunity to Mycobacteria in most, if not all, patients. </plain></SENT>
</text></p><p><text><SENT sid="178" pm="."><plain>The prognosis of IL-12Rβ1 deficiency is good due to the low clinical penetrance of primary mycobacterial infection, acquired protective immunity to secondary mycobacterial infection, and the lack of life-threatening nonmycobacterial infections. </plain></SENT>
<SENT sid="179" pm="."><plain>Only 5 of our 41 (12%) IL-12Rβ1–deficient patients died of BCG or EM infection, before the age of 8 yr. </plain></SENT>
<SENT sid="180" pm="."><plain>The overall mortality rate for all known IL-12Rβ1–deficient patients is only 15% (7/48), increasing to 21% (13/63) if we include IL-12p40–deficient children (13–15, 17, 18, 21). </plain></SENT>
<SENT sid="181" pm="."><plain>Outcome improved with age, and our patients (now aged 2–33 yr) are healthy and off all treatment. </plain></SENT>
<SENT sid="182" pm="."><plain>These results should help us to predict clinical outcome for individual patients. </plain></SENT>
<SENT sid="183" pm="."><plain>They also indicate that immune mechanisms progressively develop ways of compensating for the lack of IL-12–mediated immunity. </plain></SENT>
</text></p><p><text><SENT sid="184" pm="."><plain>21 of the 41 patients (51%) in our series had had extra-intestinal infections caused by Salmonella, as had 4 of the other 7 IL-12Rβ1–deficient patients (15, 17, 18, 21) and 5 of the 15 IL-12p40–deficient patients (a total of 30 out of 63, 48%; references 13–15). </plain></SENT>
<SENT sid="185" pm="."><plain>Of clinical interest, five children presented salmonellosis as the only infectious disease. </plain></SENT>
<SENT sid="186" pm="."><plain>IL-12 has been shown to play a major role in host defense against Salmonella in IL-12p40-KO mice (33, 34). </plain></SENT>
<SENT sid="187" pm="."><plain>Our observation extends this findings in humans. </plain></SENT>
<SENT sid="188" pm="."><plain>However, not all Salmonella-infected patients developed clinical disease (Table I). </plain></SENT>
<SENT sid="189" pm="."><plain>IL-12 was redundant in primary immunity against Salmonella in some patients. </plain></SENT>
<SENT sid="190" pm="."><plain>Salmonellosis recurrence was frequent (8/21, 38%), suggesting that IL-12 is required for secondary immunity to Salmonella in many patients. </plain></SENT>
<SENT sid="191" pm="."><plain>These data suggest that different immune mechanisms control secondary immunity to Salmonella and Mycobacteria. </plain></SENT>
</text></p><p><text><SENT sid="192" pm="."><plain>There were no other unusually severe infections in our 41 patients, as in the other seven patients (15, 17, 18, 21; Table I). </plain></SENT>
<SENT sid="193" pm="."><plain>CMV infection had been well controlled in at least 14 patients (Table I). </plain></SENT>
<SENT sid="194" pm="."><plain>Other common viruses did not cause severe disease in our patients. </plain></SENT>
<SENT sid="195" pm="."><plain>One patient suffered benign infection with Kingella kingae. </plain></SENT>
<SENT sid="196" pm="."><plain>There were no other diseases caused by common bacteria, including macrophage-infecting species such as Listeria and Nocardia. </plain></SENT>
<SENT sid="197" pm="."><plain>One IL-12–deficient patient had one episode of nocardiosis (14). Paracoccidioides brasiliensis infection in one curable IL-12Rβ1–deficient patient had a symptomatic yet benign course, and oral candidiasis was diagnosed in a few patients. </plain></SENT>
<SENT sid="198" pm="."><plain>Other fungi represented no threat to IL-12Rβ1–deficient patients. Toxoplasma gondii infection had an uneventful course in at least five patients. </plain></SENT>
<SENT sid="199" pm="."><plain>Other common opportunistic protozoa were not pathogenic. </plain></SENT>
</text></p><p><text><SENT sid="200" pm="."><plain>The number of kindreds investigated from various genetic backgrounds and exposed to a variety of environmental conditions, together with the number of siblings affected, ruling out a major ascertainment bias, make it possible to conclude that mycobacteriosis and salmonellosis are the most frequent infectious diseases in patients with IL-12Rβ1 deficiency. </plain></SENT>
<SENT sid="201" pm="."><plain>Our study does not exclude the possibility that other infectious or non-infectious diseases may occur in other patients with this genetic defect, or in our patients later in life. </plain></SENT>
<SENT sid="202" pm="."><plain>The apparent resistance of IL-12Rβ1–deficient patients to most microorganisms nevertheless contrasts with results obtained in mice. </plain></SENT>
<SENT sid="203" pm="."><plain>Indeed, IL12p40 KO mice are susceptible to almost all microorganisms tested (35–51). </plain></SENT>
<SENT sid="204" pm="."><plain>The lack of a requirement for IL-12 and probably IL-23 for protective immunity against most microorganisms in humans may reflect the natural (1), as opposed to experimental, course of most infections in man. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="205" pm="."><plain>We would like to thank the patients and their families, the members of the Laboratory of Human Genetics of Infectious Diseases, Dr. Dominique Recan for the EBV transformation of B cells, and Dr. Sandra Weller for invaluable advice in flow cytometry. </plain></SENT>
</text></text4fund></p><p><text4fund><text><SENT sid="206" pm="."><plain>C. </plain></SENT>
<SENT sid="207" pm="."><plain>Fieschi was supported by the Association pour la Recherche contre le Cancer (ARC), S. </plain></SENT>
<SENT sid="208" pm="."><plain>Dupuis by the Ministere de l'Education Nationale, de la Recherche, et de la Technologie (MENRT), and J. </plain></SENT>
<SENT sid="209" pm="."><plain>Bustamante by the Fondation Schlumberger. </plain></SENT>
<SENT sid="210" pm="."><plain>This work was supported by the Fondation BNP-Paribas, the Fondation Schlumberger, and the Sequella Foundation. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><fn id="fn1"><label>*</label><p><text><SENT sid="211" pm="."><plain>Abbreviations used in this paper: BCG, Bacille Calmette-Guérin; EM, environmental Mycobacteria; SSCP, single-stranded conformation polymorphism. </plain></SENT>
</text></p></fn></fn-group><SecTag type="REF"><ref-list><ref id="bib1"><text><SENT sid="212" pm="."><plain>1Casanova, J.L., and L. </plain></SENT>
<SENT sid="213" pm="."><plain>Abel. 2002. </plain></SENT>
<SENT sid="214" pm="."><plain>Genetic dissection of immunity to mycobacteria: The human model. Annu. </plain></SENT>
<SENT sid="215" pm="."><plain>Rev. </plain></SENT>
<SENT sid="216" pm="."><plain>Immunol. 20:581–620. <?supplied-pmid 11861613?>11861613 </plain></SENT>
</text></ref><ref id="bib2"><text><SENT sid="217" pm="."><plain>2Casanova, J.L., S. </plain></SENT>
<SENT sid="218" pm="."><plain>Blanche, J.F. </plain></SENT>
<SENT sid="219" pm="."><plain>Emile, E. </plain></SENT>
<SENT sid="220" pm="."><plain>Jouanguy, S. </plain></SENT>
<SENT sid="221" pm="."><plain>Lamhamedi, F. </plain></SENT>
<SENT sid="222" pm="."><plain>Altare, J.L. </plain></SENT>
<SENT sid="223" pm="."><plain>Stephan, F. </plain></SENT>
<SENT sid="224" pm="."><plain>Bernaudin, P. </plain></SENT>
<SENT sid="225" pm="."><plain>Bordigoni, D. </plain></SENT>
<SENT sid="226" pm="."><plain>Turck, et al. 1996. </plain></SENT>
<SENT sid="227" pm="."><plain>Idiopathic disseminated bacillus Calmette-Guerin infection: a French national retrospective study. Pediatrics. 98:774–778. <?supplied-pmid 8885960?>8885960 </plain></SENT>
</text></ref><ref id="bib3"><text><SENT sid="228" pm="."><plain>3Levin, M., M.J. </plain></SENT>
<SENT sid="229" pm="."><plain>Newport, S. </plain></SENT>
<SENT sid="230" pm="."><plain>D'Souza, P. </plain></SENT>
<SENT sid="231" pm="."><plain>Kalabalikis, I.N. </plain></SENT>
<SENT sid="232" pm="."><plain>Brown, H.M. </plain></SENT>
<SENT sid="233" pm="."><plain>Lenicker, P.V. </plain></SENT>
<SENT sid="234" pm="."><plain>Agius, E.G. </plain></SENT>
<SENT sid="235" pm="."><plain>Davies, A. </plain></SENT>
<SENT sid="236" pm="."><plain>Thrasher, N. </plain></SENT>
<SENT sid="237" pm="."><plain>Klein, and J. </plain></SENT>
<SENT sid="238" pm="."><plain>Blackwell. 1995. </plain></SENT>
<SENT sid="239" pm="."><plain>Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene? Lancet. 345:79–83. <?supplied-pmid 7815885?>7815885 </plain></SENT>
</text></ref><ref id="bib4"><text><SENT sid="240" pm="."><plain>4Jouanguy, E., S. </plain></SENT>
<SENT sid="241" pm="."><plain>Lamhamedi-Cherradi, D. </plain></SENT>
<SENT sid="242" pm="."><plain>Lammas, S.E. </plain></SENT>
<SENT sid="243" pm="."><plain>Dorman, M.-C. </plain></SENT>
<SENT sid="244" pm="."><plain>Fondanèche, S. </plain></SENT>
<SENT sid="245" pm="."><plain>Dupuis, R. </plain></SENT>
<SENT sid="246" pm="."><plain>Döffinger, F. </plain></SENT>
<SENT sid="247" pm="."><plain>Altare, J.-F. </plain></SENT>
<SENT sid="248" pm="."><plain>Emile, J. </plain></SENT>
<SENT sid="249" pm="."><plain>Girdelstone, et al. 1999. </plain></SENT>
<SENT sid="250" pm="."><plain>A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat. </plain></SENT>
<SENT sid="251" pm="."><plain>Genet. 21:370–378. <?supplied-pmid 10192386?>10192386 </plain></SENT>
</text></ref><ref id="bib5"><text><SENT sid="252" pm="."><plain>5Frucht, D.M., and S.M. </plain></SENT>
<SENT sid="253" pm="."><plain>Holland. 1996. </plain></SENT>
<SENT sid="254" pm="."><plain>Defective monocyte costimulation for IFN-gamma production in familial disseminated Mycobacterium avium complex infection: abnormal IL-12 regulation. J. </plain></SENT>
<SENT sid="255" pm="."><plain>Immunol. 157:411–416. <?supplied-pmid 8683146?>8683146 </plain></SENT>
</text></ref><ref id="bib6"><text><SENT sid="256" pm="."><plain>6Newport, M.J., C.M. </plain></SENT>
<SENT sid="257" pm="."><plain>Huxley, S. </plain></SENT>
<SENT sid="258" pm="."><plain>Huston, C.M. </plain></SENT>
<SENT sid="259" pm="."><plain>Hawrylowicz, B.A. </plain></SENT>
<SENT sid="260" pm="."><plain>Oostra, R. </plain></SENT>
<SENT sid="261" pm="."><plain>Williamson, and M. </plain></SENT>
<SENT sid="262" pm="."><plain>Levin. 1996. </plain></SENT>
<SENT sid="263" pm="."><plain>A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N. </plain></SENT>
<SENT sid="264" pm="."><plain>Engl. </plain></SENT>
<SENT sid="265" pm="."><plain>J. </plain></SENT>
<SENT sid="266" pm="."><plain>Med. 335:1941–1949. <?supplied-pmid 8960473?>8960473 </plain></SENT>
</text></ref><ref id="bib7"><text><SENT sid="267" pm="."><plain>7Jouanguy, E., F. </plain></SENT>
<SENT sid="268" pm="."><plain>Altare, S. </plain></SENT>
<SENT sid="269" pm="."><plain>Lamhamedi, P. </plain></SENT>
<SENT sid="270" pm="."><plain>Revy, J.F. </plain></SENT>
<SENT sid="271" pm="."><plain>Emile, M. </plain></SENT>
<SENT sid="272" pm="."><plain>Newport, M. </plain></SENT>
<SENT sid="273" pm="."><plain>Levin, S. </plain></SENT>
<SENT sid="274" pm="."><plain>Blanche, E. </plain></SENT>
<SENT sid="275" pm="."><plain>Seboun, A. </plain></SENT>
<SENT sid="276" pm="."><plain>Fischer, and J.L. </plain></SENT>
<SENT sid="277" pm="."><plain>Casanova. 1996. </plain></SENT>
<SENT sid="278" pm="."><plain>Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N. </plain></SENT>
<SENT sid="279" pm="."><plain>Engl. </plain></SENT>
<SENT sid="280" pm="."><plain>J. </plain></SENT>
<SENT sid="281" pm="."><plain>Med. 335:1956–1961. <?supplied-pmid 8960475?>8960475 </plain></SENT>
</text></ref><ref id="bib8"><text><SENT sid="282" pm="."><plain>8Jouanguy, E., S. </plain></SENT>
<SENT sid="283" pm="."><plain>Dupuis, A. </plain></SENT>
<SENT sid="284" pm="."><plain>Pallier, R. </plain></SENT>
<SENT sid="285" pm="."><plain>Doffinger, M.C. </plain></SENT>
<SENT sid="286" pm="."><plain>Fondaneche, C. </plain></SENT>
<SENT sid="287" pm="."><plain>Fieschi, S. </plain></SENT>
<SENT sid="288" pm="."><plain>Lamhamedi-Cherradi, F. </plain></SENT>
<SENT sid="289" pm="."><plain>Altare, J.F. </plain></SENT>
<SENT sid="290" pm="."><plain>Emile, P. </plain></SENT>
<SENT sid="291" pm="."><plain>Lutz, et al. 2000. </plain></SENT>
<SENT sid="292" pm="."><plain>In a novel form of IFN-gamma receptor 1 deficiency, cell surface receptors fail to bind IFN-gamma. J. </plain></SENT>
<SENT sid="293" pm="."><plain>Clin. </plain></SENT>
<SENT sid="294" pm="."><plain>Invest. 105:1429–1436. <?supplied-pmid 10811850?>10811850 </plain></SENT>
</text></ref><ref id="bib9"><text><SENT sid="295" pm="."><plain>9Jouanguy, E., S. </plain></SENT>
<SENT sid="296" pm="."><plain>Lamhamedi-Cherradi, F. </plain></SENT>
<SENT sid="297" pm="."><plain>Altare, M.C. </plain></SENT>
<SENT sid="298" pm="."><plain>Fondaneche, D. </plain></SENT>
<SENT sid="299" pm="."><plain>Tuerlinckx, S. </plain></SENT>
<SENT sid="300" pm="."><plain>Blanche, J.F. </plain></SENT>
<SENT sid="301" pm="."><plain>Emile, J.L. </plain></SENT>
<SENT sid="302" pm="."><plain>Gaillard, R. </plain></SENT>
<SENT sid="303" pm="."><plain>Schreiber, M. </plain></SENT>
<SENT sid="304" pm="."><plain>Levin, et al. 1997. </plain></SENT>
<SENT sid="305" pm="."><plain>Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis. J. </plain></SENT>
<SENT sid="306" pm="."><plain>Clin. </plain></SENT>
<SENT sid="307" pm="."><plain>Invest. 100:2658–2664. <?supplied-pmid 9389728?>9389728 </plain></SENT>
</text></ref><ref id="bib10"><text><SENT sid="308" pm="."><plain>10Dorman, S.E., and S.M. </plain></SENT>
<SENT sid="309" pm="."><plain>Holland. 1998. </plain></SENT>
<SENT sid="310" pm="."><plain>Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J. </plain></SENT>
<SENT sid="311" pm="."><plain>Clin. </plain></SENT>
<SENT sid="312" pm="."><plain>Invest. 101:2364–2369. <?supplied-pmid 9616207?>9616207 </plain></SENT>
</text></ref><ref id="bib11"><text><SENT sid="313" pm="."><plain>11Döffinger, R., E. </plain></SENT>
<SENT sid="314" pm="."><plain>Jouanguy, S. </plain></SENT>
<SENT sid="315" pm="."><plain>Dupuis, M.C. </plain></SENT>
<SENT sid="316" pm="."><plain>Fondanèche, J.L. </plain></SENT>
<SENT sid="317" pm="."><plain>Stéphan, J.F. </plain></SENT>
<SENT sid="318" pm="."><plain>Emile, S. </plain></SENT>
<SENT sid="319" pm="."><plain>Lamhamedi, F. </plain></SENT>
<SENT sid="320" pm="."><plain>Altare, A. </plain></SENT>
<SENT sid="321" pm="."><plain>Pallier, G. </plain></SENT>
<SENT sid="322" pm="."><plain>Barcenas-Morales, et al. 2000. </plain></SENT>
<SENT sid="323" pm="."><plain>Partial interferon gamma receptor signalling chain deficiency in a patient with bacille Calmette-Guérin and Mycobacterium abscessus infection. J. </plain></SENT>
<SENT sid="324" pm="."><plain>Infect. </plain></SENT>
<SENT sid="325" pm="."><plain>Dis. 181:379–384. <?supplied-pmid 10608793?>10608793 </plain></SENT>
</text></ref><ref id="bib12"><text><SENT sid="326" pm="."><plain>12Dupuis, S., C. </plain></SENT>
<SENT sid="327" pm="."><plain>Dargemont, C. </plain></SENT>
<SENT sid="328" pm="."><plain>Fieschi, N. </plain></SENT>
<SENT sid="329" pm="."><plain>Thomassin, S. </plain></SENT>
<SENT sid="330" pm="."><plain>Rosenzweig, J. </plain></SENT>
<SENT sid="331" pm="."><plain>Harris, S.M. </plain></SENT>
<SENT sid="332" pm="."><plain>Holland, R.D. </plain></SENT>
<SENT sid="333" pm="."><plain>Schreiber, and J.L. </plain></SENT>
<SENT sid="334" pm="."><plain>Casanova. 2001. </plain></SENT>
<SENT sid="335" pm="."><plain>Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science. 293:300–303. <?supplied-pmid 11452125?>11452125 </plain></SENT>
</text></ref><ref id="bib13"><text><SENT sid="336" pm="."><plain>13Altare, F., D. </plain></SENT>
<SENT sid="337" pm="."><plain>Lammas, P. </plain></SENT>
<SENT sid="338" pm="."><plain>Revy, E. </plain></SENT>
<SENT sid="339" pm="."><plain>Jouanguy, R. </plain></SENT>
<SENT sid="340" pm="."><plain>Döffinger, S. </plain></SENT>
<SENT sid="341" pm="."><plain>Lamhamedi, P. </plain></SENT>
<SENT sid="342" pm="."><plain>Drysdale, D. </plain></SENT>
<SENT sid="343" pm="."><plain>Tollner, J. </plain></SENT>
<SENT sid="344" pm="."><plain>Girdlestone, P. </plain></SENT>
<SENT sid="345" pm="."><plain>Darbyshire, et al. 1998. </plain></SENT>
<SENT sid="346" pm="."><plain>Inherited interleukin 12 deficiency in a child with bacille Calmette-Guérin and Salmonella enteritidis disseminated infection. J. </plain></SENT>
<SENT sid="347" pm="."><plain>Clin. </plain></SENT>
<SENT sid="348" pm="."><plain>Invest. 102:2035–2040. <?supplied-pmid 9854038?>9854038 </plain></SENT>
</text></ref><ref id="bib14"><text><SENT sid="349" pm="."><plain>14Picard, C., C. </plain></SENT>
<SENT sid="350" pm="."><plain>Fieschi, F. </plain></SENT>
<SENT sid="351" pm="."><plain>Altare, S. </plain></SENT>
<SENT sid="352" pm="."><plain>Al-Jumaah, S. </plain></SENT>
<SENT sid="353" pm="."><plain>Al-Hajjar, J. </plain></SENT>
<SENT sid="354" pm="."><plain>Feinberg, S. </plain></SENT>
<SENT sid="355" pm="."><plain>Dupuis, C. </plain></SENT>
<SENT sid="356" pm="."><plain>Soudais, I.Z. </plain></SENT>
<SENT sid="357" pm="."><plain>Al-Mohsen, E. </plain></SENT>
<SENT sid="358" pm="."><plain>Genin, et al. 2002. </plain></SENT>
<SENT sid="359" pm="."><plain>Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am. </plain></SENT>
<SENT sid="360" pm="."><plain>J. </plain></SENT>
<SENT sid="361" pm="."><plain>Hum. </plain></SENT>
<SENT sid="362" pm="."><plain>Genet. 70:336–348. <?supplied-pmid 11753820?>11753820 </plain></SENT>
</text></ref><ref id="bib15"><text><SENT sid="363" pm="."><plain>15Elloumi-Zghal, H., M.R. </plain></SENT>
<SENT sid="364" pm="."><plain>Barbouche, J. </plain></SENT>
<SENT sid="365" pm="."><plain>Chemli, M. </plain></SENT>
<SENT sid="366" pm="."><plain>Bejaoui, A. </plain></SENT>
<SENT sid="367" pm="."><plain>Harbi, N. </plain></SENT>
<SENT sid="368" pm="."><plain>Snoussi, S. </plain></SENT>
<SENT sid="369" pm="."><plain>Abdelhak, and K. </plain></SENT>
<SENT sid="370" pm="."><plain>Dellagi. 2002. </plain></SENT>
<SENT sid="371" pm="."><plain>Clinical and genetic heterogeneity of inherited autosomal recessive susceptibility to disseminated Mycobacterium bovis Bacille Calmette-Guerin infection. J. </plain></SENT>
<SENT sid="372" pm="."><plain>Infect. </plain></SENT>
<SENT sid="373" pm="."><plain>Dis. 185:1468–1475. <?supplied-pmid 11992283?>11992283 </plain></SENT>
</text></ref><ref id="bib16"><text><SENT sid="374" pm="."><plain>16Altare, F., A. </plain></SENT>
<SENT sid="375" pm="."><plain>Durandy, D. </plain></SENT>
<SENT sid="376" pm="."><plain>Lammas, J.F. </plain></SENT>
<SENT sid="377" pm="."><plain>Emile, S. </plain></SENT>
<SENT sid="378" pm="."><plain>Lamhamedi, F. </plain></SENT>
<SENT sid="379" pm="."><plain>Le Deist, P. </plain></SENT>
<SENT sid="380" pm="."><plain>Drysdale, E. </plain></SENT>
<SENT sid="381" pm="."><plain>Jouanguy, R. </plain></SENT>
<SENT sid="382" pm="."><plain>Döffinger, F. </plain></SENT>
<SENT sid="383" pm="."><plain>Bernaudin, et al. 1998. </plain></SENT>
<SENT sid="384" pm="."><plain>Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science. 280:1432–1435. <?supplied-pmid 9603732?>9603732 </plain></SENT>
</text></ref><ref id="bib17"><text><SENT sid="385" pm="."><plain>17de Jong, R., F. </plain></SENT>
<SENT sid="386" pm="."><plain>Altare, I.A. </plain></SENT>
<SENT sid="387" pm="."><plain>Haagen, D.G. </plain></SENT>
<SENT sid="388" pm="."><plain>Elferink, T. </plain></SENT>
<SENT sid="389" pm="."><plain>Boer, P.J. van Breda Vriesman, P.J. </plain></SENT>
<SENT sid="390" pm="."><plain>Kabel, J.M. </plain></SENT>
<SENT sid="391" pm="."><plain>Draaisma, J.T. van Dissel, F.P. </plain></SENT>
<SENT sid="392" pm="."><plain>Kroon, et al. 1998. </plain></SENT>
<SENT sid="393" pm="."><plain>Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science. 280:1435–1438. <?supplied-pmid 9603733?>9603733 </plain></SENT>
</text></ref><ref id="bib18"><text><SENT sid="394" pm="."><plain>18Verhagen, C.E., T. de Boer, H.H. </plain></SENT>
<SENT sid="395" pm="."><plain>Smits, F.A. </plain></SENT>
<SENT sid="396" pm="."><plain>Verreck, E.A. </plain></SENT>
<SENT sid="397" pm="."><plain>Wierenga, M. </plain></SENT>
<SENT sid="398" pm="."><plain>Kurimoto, D.A. </plain></SENT>
<SENT sid="399" pm="."><plain>Lammas, D.S. </plain></SENT>
<SENT sid="400" pm="."><plain>Kumararatne, O. </plain></SENT>
<SENT sid="401" pm="."><plain>Sanal, F.P. </plain></SENT>
<SENT sid="402" pm="."><plain>Kroon, et al. 2000. </plain></SENT>
<SENT sid="403" pm="."><plain>Residual type 1 immunity in patients genetically deficient for interleukin 12 receptor beta1 (IL-12Rbeta1): evidence for an IL-12Rbeta1-independent pathway of IL-12 responsiveness in human T cells. J. </plain></SENT>
<SENT sid="404" pm="."><plain>Exp. </plain></SENT>
<SENT sid="405" pm="."><plain>Med. 192:517–528. <?supplied-pmid 10952721?>10952721 </plain></SENT>
</text></ref><ref id="bib19"><text><SENT sid="406" pm="."><plain>19Aksu, G., C. </plain></SENT>
<SENT sid="407" pm="."><plain>Tirpan, C. </plain></SENT>
<SENT sid="408" pm="."><plain>Cavusoglu, S. </plain></SENT>
<SENT sid="409" pm="."><plain>Soydan, F. </plain></SENT>
<SENT sid="410" pm="."><plain>Altare, J.L. </plain></SENT>
<SENT sid="411" pm="."><plain>Casanova, and N. </plain></SENT>
<SENT sid="412" pm="."><plain>Kutukculer. 2001. </plain></SENT>
<SENT sid="413" pm="."><plain>Mycobacterium fortuitum-chelonae complex infection in a child with complete interleukin-12 receptor beta 1 deficiency. Pediatr. </plain></SENT>
<SENT sid="414" pm="."><plain>Infect. </plain></SENT>
<SENT sid="415" pm="."><plain>Dis. </plain></SENT>
<SENT sid="416" pm="."><plain>J. 20:551–553. <?supplied-pmid 11368122?>11368122 </plain></SENT>
</text></ref><ref id="bib20"><text><SENT sid="417" pm="."><plain>20Altare, F., A. </plain></SENT>
<SENT sid="418" pm="."><plain>Ensser, A. </plain></SENT>
<SENT sid="419" pm="."><plain>Breiman, J. </plain></SENT>
<SENT sid="420" pm="."><plain>Reichenbach, J.E. </plain></SENT>
<SENT sid="421" pm="."><plain>Baghdadi, A. </plain></SENT>
<SENT sid="422" pm="."><plain>Fischer, J.F. </plain></SENT>
<SENT sid="423" pm="."><plain>Emile, J.L. </plain></SENT>
<SENT sid="424" pm="."><plain>Gaillard, E. </plain></SENT>
<SENT sid="425" pm="."><plain>Meinl, and J.L. </plain></SENT>
<SENT sid="426" pm="."><plain>Casanova. 2001. </plain></SENT>
<SENT sid="427" pm="."><plain>Interleukin-12 receptor beta1 deficiency in a patient with abdominal tuberculosis. J. </plain></SENT>
<SENT sid="428" pm="."><plain>Infect. </plain></SENT>
<SENT sid="429" pm="."><plain>Dis. 184:231–236. <?supplied-pmid 11424023?>11424023 </plain></SENT>
</text></ref><ref id="bib21"><text><SENT sid="430" pm="."><plain>21Sakai, T., M. </plain></SENT>
<SENT sid="431" pm="."><plain>Matsuoka, M. </plain></SENT>
<SENT sid="432" pm="."><plain>Aoki, K. </plain></SENT>
<SENT sid="433" pm="."><plain>Nosaka, and H. </plain></SENT>
<SENT sid="434" pm="."><plain>Mitsuya. 2001. </plain></SENT>
<SENT sid="435" pm="."><plain>Missense mutation of the interleukin-12 receptor beta1 chain-encoding gene is associated with impaired immunity against Mycobacterium avium complex infection. Blood. 97:2688–2694. <?supplied-pmid 11313259?>11313259 </plain></SENT>
</text></ref><ref id="bib22"><text><SENT sid="436" pm="."><plain>22Romani, L., P. </plain></SENT>
<SENT sid="437" pm="."><plain>Puccetti, and F. </plain></SENT>
<SENT sid="438" pm="."><plain>Bistoni. 1997. </plain></SENT>
<SENT sid="439" pm="."><plain>Interleukin-12 in infectious diseases. Clin. </plain></SENT>
<SENT sid="440" pm="."><plain>Microbiol. </plain></SENT>
<SENT sid="441" pm="."><plain>Rev. 10:611–636. <?supplied-pmid 9336665?>9336665 </plain></SENT>
</text></ref><ref id="bib23"><text><SENT sid="442" pm="."><plain>23Gately, M.K., L.M. </plain></SENT>
<SENT sid="443" pm="."><plain>Renzetti, J. </plain></SENT>
<SENT sid="444" pm="."><plain>Magram, A.S. </plain></SENT>
<SENT sid="445" pm="."><plain>Stern, L. </plain></SENT>
<SENT sid="446" pm="."><plain>Adorini, U. </plain></SENT>
<SENT sid="447" pm="."><plain>Gubler, and D.H. </plain></SENT>
<SENT sid="448" pm="."><plain>Presky. 1998. </plain></SENT>
<SENT sid="449" pm="."><plain>The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. </plain></SENT>
<SENT sid="450" pm="."><plain>Rev. </plain></SENT>
<SENT sid="451" pm="."><plain>Immunol. 16:495–521. <?supplied-pmid 9597139?>9597139 </plain></SENT>
</text></ref><ref id="bib24"><text><SENT sid="452" pm="."><plain>24Murphy, K.M., and S.L. </plain></SENT>
<SENT sid="453" pm="."><plain>Reiner. 2002. </plain></SENT>
<SENT sid="454" pm="."><plain>Decision making in the immune system: the lineage decisions of helper T cells. Nat. </plain></SENT>
<SENT sid="455" pm="."><plain>Rev. </plain></SENT>
<SENT sid="456" pm="."><plain>Immunol. 2:933–944. <?supplied-pmid 12461566?>12461566 </plain></SENT>
</text></ref><ref id="bib25"><text><SENT sid="457" pm="."><plain>25Parham, C., M. </plain></SENT>
<SENT sid="458" pm="."><plain>Chirica, J. </plain></SENT>
<SENT sid="459" pm="."><plain>Timans, E. </plain></SENT>
<SENT sid="460" pm="."><plain>Vaisberg, M. </plain></SENT>
<SENT sid="461" pm="."><plain>Travis, J. </plain></SENT>
<SENT sid="462" pm="."><plain>Cheung, S. </plain></SENT>
<SENT sid="463" pm="."><plain>Pflanz, R. </plain></SENT>
<SENT sid="464" pm="."><plain>Zhang, K.P. </plain></SENT>
<SENT sid="465" pm="."><plain>Singh, F. </plain></SENT>
<SENT sid="466" pm="."><plain>Vega, et al. 2002. </plain></SENT>
<SENT sid="467" pm="."><plain>A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. </plain></SENT>
<SENT sid="468" pm="."><plain>Immunol. 168:5699–5708. <?supplied-pmid 12023369?>12023369 </plain></SENT>
</text></ref><ref id="bib26"><text><SENT sid="469" pm="."><plain>26Magram, J., S.E. </plain></SENT>
<SENT sid="470" pm="."><plain>Connaughton, R.R. </plain></SENT>
<SENT sid="471" pm="."><plain>Warrier, D.M. </plain></SENT>
<SENT sid="472" pm="."><plain>Carvajal, C.Y. </plain></SENT>
<SENT sid="473" pm="."><plain>Wu, J. </plain></SENT>
<SENT sid="474" pm="."><plain>Ferrante, C. </plain></SENT>
<SENT sid="475" pm="."><plain>Stewart, U. </plain></SENT>
<SENT sid="476" pm="."><plain>Sarmiento, D.A. </plain></SENT>
<SENT sid="477" pm="."><plain>Faherty, and M.K. </plain></SENT>
<SENT sid="478" pm="."><plain>Gately. 1996. </plain></SENT>
<SENT sid="479" pm="."><plain>IL-12-deficient mice are defective in IFNγ production and type 1 cytokine responses. Immunity. 4:471–481. <?supplied-pmid 8630732?>8630732 </plain></SENT>
</text></ref><ref id="bib27"><text><SENT sid="480" pm="."><plain>27Hölscher, C., R.A. </plain></SENT>
<SENT sid="481" pm="."><plain>Atkinson, B. </plain></SENT>
<SENT sid="482" pm="."><plain>Arendse, N. </plain></SENT>
<SENT sid="483" pm="."><plain>Brown, E. </plain></SENT>
<SENT sid="484" pm="."><plain>Myburgh, G. </plain></SENT>
<SENT sid="485" pm="."><plain>Alber, and F. </plain></SENT>
<SENT sid="486" pm="."><plain>Brombacher. 2001. </plain></SENT>
<SENT sid="487" pm="."><plain>A protective and agonistic function of IL-12p40 in mycobacterial infection. J. </plain></SENT>
<SENT sid="488" pm="."><plain>Immunol. 167:6957–6966. <?supplied-pmid 11739515?>11739515 </plain></SENT>
</text></ref><ref id="bib28"><text><SENT sid="489" pm="."><plain>28Cooper, A.M., J. </plain></SENT>
<SENT sid="490" pm="."><plain>Magram, J. </plain></SENT>
<SENT sid="491" pm="."><plain>Ferrante, and I.M. </plain></SENT>
<SENT sid="492" pm="."><plain>Orme. 1997. </plain></SENT>
<SENT sid="493" pm="."><plain>Interleukin 12 is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J. </plain></SENT>
<SENT sid="494" pm="."><plain>Exp. </plain></SENT>
<SENT sid="495" pm="."><plain>Med. 186:39–45. <?supplied-pmid 9206995?>9206995 </plain></SENT>
</text></ref><ref id="bib29"><text><SENT sid="496" pm="."><plain>29Cooper, A.M., A. </plain></SENT>
<SENT sid="497" pm="."><plain>Kipnis, J. </plain></SENT>
<SENT sid="498" pm="."><plain>Turner, J. </plain></SENT>
<SENT sid="499" pm="."><plain>Magram, J. </plain></SENT>
<SENT sid="500" pm="."><plain>Ferrante, and I.M. </plain></SENT>
<SENT sid="501" pm="."><plain>Orme. 2002. </plain></SENT>
<SENT sid="502" pm="."><plain>Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J. </plain></SENT>
<SENT sid="503" pm="."><plain>Immunol. 168:1322–1327. <?supplied-pmid 11801672?>11801672 </plain></SENT>
</text></ref><ref id="bib30"><text><SENT sid="504" pm="."><plain>30Doherty, T.M., and A. </plain></SENT>
<SENT sid="505" pm="."><plain>Sher. 1998. </plain></SENT>
<SENT sid="506" pm="."><plain>IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J. </plain></SENT>
<SENT sid="507" pm="."><plain>Immunol. 160:5428–5435. <?supplied-pmid 9605144?>9605144 </plain></SENT>
</text></ref><ref id="bib31"><text><SENT sid="508" pm="."><plain>31Silva, R.A., M. </plain></SENT>
<SENT sid="509" pm="."><plain>Florido, and R. </plain></SENT>
<SENT sid="510" pm="."><plain>Appelberg. 2001. </plain></SENT>
<SENT sid="511" pm="."><plain>Interleukin-12 primes CD4+ T cells for interferon-gamma production and protective immunity during Mycobacterium avium infection. Immunology. 103:368–374. <?supplied-pmid 11454066?>11454066 </plain></SENT>
</text></ref><ref id="bib32"><text><SENT sid="512" pm="."><plain>32Ehlers, S., J. </plain></SENT>
<SENT sid="513" pm="."><plain>Benini, H.D. </plain></SENT>
<SENT sid="514" pm="."><plain>Held, C. </plain></SENT>
<SENT sid="515" pm="."><plain>Roeck, G. </plain></SENT>
<SENT sid="516" pm="."><plain>Alber, and S. </plain></SENT>
<SENT sid="517" pm="."><plain>Uhlig. 2001. alphabeta T cell receptor-positive cells and interferon-gamma, but not inducible nitric oxide synthase, are critical for granuloma necrosis in a mouse model of mycobacteria-induced pulmonary immunopathology. J. </plain></SENT>
<SENT sid="518" pm="."><plain>Exp. </plain></SENT>
<SENT sid="519" pm="."><plain>Med. 194:1847–1859. <?supplied-pmid 11748285?>11748285 </plain></SENT>
</text></ref><ref id="bib33"><text><SENT sid="520" pm="."><plain>33Dybing, J.K., N. </plain></SENT>
<SENT sid="521" pm="."><plain>Walters, and D.W. </plain></SENT>
<SENT sid="522" pm="."><plain>Pascual. 1999. </plain></SENT>
<SENT sid="523" pm="."><plain>Role of endogenous interleukin-18 in resolving wild-type and attenuated Salmonella typhimurium infections. Infect. </plain></SENT>
<SENT sid="524" pm="."><plain>Immun. 67:6242–6248. <?supplied-pmid 10569733?>10569733 </plain></SENT>
</text></ref><ref id="bib34"><text><SENT sid="525" pm="."><plain>34Lehmann, J., S. </plain></SENT>
<SENT sid="526" pm="."><plain>Bellmann, C. </plain></SENT>
<SENT sid="527" pm="."><plain>Werner, R. </plain></SENT>
<SENT sid="528" pm="."><plain>Schroder, N. </plain></SENT>
<SENT sid="529" pm="."><plain>Schutze, and G. </plain></SENT>
<SENT sid="530" pm="."><plain>Alber. 2001. </plain></SENT>
<SENT sid="531" pm="."><plain>IL-12p40-dependent agonistic effects on the development of protective innate and adaptive immunity against Salmonella enteritidis. J. </plain></SENT>
<SENT sid="532" pm="."><plain>Immunol. 167:5304–5315. <?supplied-pmid 11673546?>11673546 </plain></SENT>
</text></ref><ref id="bib35"><text><SENT sid="533" pm="."><plain>35Lu, H., X. </plain></SENT>
<SENT sid="534" pm="."><plain>Yang, K. </plain></SENT>
<SENT sid="535" pm="."><plain>Takeda, D. </plain></SENT>
<SENT sid="536" pm="."><plain>Zhang, Y. </plain></SENT>
<SENT sid="537" pm="."><plain>Fan, M. </plain></SENT>
<SENT sid="538" pm="."><plain>Luo, C. </plain></SENT>
<SENT sid="539" pm="."><plain>Shen, S. </plain></SENT>
<SENT sid="540" pm="."><plain>Wang, S. </plain></SENT>
<SENT sid="541" pm="."><plain>Akira, and R.C. </plain></SENT>
<SENT sid="542" pm="."><plain>Brunham. 2000. </plain></SENT>
<SENT sid="543" pm="."><plain>Chlamydia trachomatis mouse pneumonitis lung infection in IL-18 and IL-12 knockout mice: IL-12 is dominant over IL-18 for protective immunity. Mol. </plain></SENT>
<SENT sid="544" pm="."><plain>Med. 6:604–612. <?supplied-pmid 10997341?>10997341 </plain></SENT>
</text></ref><ref id="bib36"><text><SENT sid="545" pm="."><plain>36Rottenberg, M.E., A. </plain></SENT>
<SENT sid="546" pm="."><plain>Gigliotti Rothfuchs, D. </plain></SENT>
<SENT sid="547" pm="."><plain>Gigliotti, M. </plain></SENT>
<SENT sid="548" pm="."><plain>Ceausu, C. </plain></SENT>
<SENT sid="549" pm="."><plain>Une, V. </plain></SENT>
<SENT sid="550" pm="."><plain>Levitsky, and H. </plain></SENT>
<SENT sid="551" pm="."><plain>Wigzell. 2000. </plain></SENT>
<SENT sid="552" pm="."><plain>Regulation and role of IFN-gamma in the innate resistance to infection with Chlamydia pneumoniae. J. </plain></SENT>
<SENT sid="553" pm="."><plain>Immunol. 164:4812–4818. <?supplied-pmid 10779789?>10779789 </plain></SENT>
</text></ref><ref id="bib37"><text><SENT sid="554" pm="."><plain>37Del Rio, L., A.J. </plain></SENT>
<SENT sid="555" pm="."><plain>Buendia, J. </plain></SENT>
<SENT sid="556" pm="."><plain>Sanchez, M.C. </plain></SENT>
<SENT sid="557" pm="."><plain>Gallego, M.R. </plain></SENT>
<SENT sid="558" pm="."><plain>Caro, N. </plain></SENT>
<SENT sid="559" pm="."><plain>Ortega, J. </plain></SENT>
<SENT sid="560" pm="."><plain>Seva, F.J. </plain></SENT>
<SENT sid="561" pm="."><plain>Pallares, F. </plain></SENT>
<SENT sid="562" pm="."><plain>Cuello, and J. </plain></SENT>
<SENT sid="563" pm="."><plain>Salinas. 2001. </plain></SENT>
<SENT sid="564" pm="."><plain>Endogenous interleukin-12 is not required for resolution of Chlamydophila abortus (Chlamydia psittaci serotype 1) infection in mice. Infect. </plain></SENT>
<SENT sid="565" pm="."><plain>Immun. 69:4808–4815. <?supplied-pmid 11447154?>11447154 </plain></SENT>
</text></ref><ref id="bib38"><text><SENT sid="566" pm="."><plain>38Simmons, C.P., N.S. </plain></SENT>
<SENT sid="567" pm="."><plain>Goncalves, M. </plain></SENT>
<SENT sid="568" pm="."><plain>Ghaem-Maghami, M. </plain></SENT>
<SENT sid="569" pm="."><plain>Bajaj-Elliott, S. </plain></SENT>
<SENT sid="570" pm="."><plain>Clare, B. </plain></SENT>
<SENT sid="571" pm="."><plain>Neves, G. </plain></SENT>
<SENT sid="572" pm="."><plain>Frankel, G. </plain></SENT>
<SENT sid="573" pm="."><plain>Dougan, and T.T. </plain></SENT>
<SENT sid="574" pm="."><plain>MacDonald. 2002. </plain></SENT>
<SENT sid="575" pm="."><plain>Impaired resistance and enhanced pathology during infection with a noninvasive, attaching-effacing enteric bacterial pathogen, Citrobacter rodentium, in mice lacking IL-12 or IFN-gamma. J. </plain></SENT>
<SENT sid="576" pm="."><plain>Immunol. 168:1804–1812. <?supplied-pmid 11823513?>11823513 </plain></SENT>
</text></ref><ref id="bib39"><text><SENT sid="577" pm="."><plain>39Oxenius, A., U. </plain></SENT>
<SENT sid="578" pm="."><plain>Karrer, R.M. </plain></SENT>
<SENT sid="579" pm="."><plain>Zinkernagel, and H. </plain></SENT>
<SENT sid="580" pm="."><plain>Hengartner. 1999. </plain></SENT>
<SENT sid="581" pm="."><plain>IL-12 is not required for induction of type 1 cytokine responses in viral infections. J. </plain></SENT>
<SENT sid="582" pm="."><plain>Immunol. 162:965–973. <?supplied-pmid 9916721?>9916721 </plain></SENT>
</text></ref><ref id="bib40"><text><SENT sid="583" pm="."><plain>40Michailowsky, V., N.M. </plain></SENT>
<SENT sid="584" pm="."><plain>Silva, C.D. </plain></SENT>
<SENT sid="585" pm="."><plain>Rocha, L.Q. </plain></SENT>
<SENT sid="586" pm="."><plain>Vieira, J. </plain></SENT>
<SENT sid="587" pm="."><plain>Lannes-Vieira, and R.T. </plain></SENT>
<SENT sid="588" pm="."><plain>Gazzinelli. 2001. </plain></SENT>
<SENT sid="589" pm="."><plain>Pivotal role of interleukin-12 and interferon-gamma axis in controlling tissue parasitism and inflammation in the heart and central nervous system during Trypanosoma cruzi infection. Am. </plain></SENT>
<SENT sid="590" pm="."><plain>J. </plain></SENT>
<SENT sid="591" pm="."><plain>Pathol. 159:1723–1733. <?supplied-pmid 11696433?>11696433 </plain></SENT>
</text></ref><ref id="bib41"><text><SENT sid="592" pm="."><plain>41Müller, U., G. </plain></SENT>
<SENT sid="593" pm="."><plain>Kohler, H. </plain></SENT>
<SENT sid="594" pm="."><plain>Mossmann, G.A. </plain></SENT>
<SENT sid="595" pm="."><plain>Schaub, G. </plain></SENT>
<SENT sid="596" pm="."><plain>Alber, J.P. </plain></SENT>
<SENT sid="597" pm="."><plain>Di Santo, F. </plain></SENT>
<SENT sid="598" pm="."><plain>Brombacher, and C. </plain></SENT>
<SENT sid="599" pm="."><plain>Holscher. 2001. </plain></SENT>
<SENT sid="600" pm="."><plain>IL-12-independent IFN-gamma production by T cells in experimental Chagas' disease is mediated by IL-18. J. </plain></SENT>
<SENT sid="601" pm="."><plain>Immunol. 167:3346–3353. <?supplied-pmid 11544324?>11544324 </plain></SENT>
</text></ref><ref id="bib42"><text><SENT sid="602" pm="."><plain>42Ely, K.H., L.H. </plain></SENT>
<SENT sid="603" pm="."><plain>Kasper, and I.A. </plain></SENT>
<SENT sid="604" pm="."><plain>Khan. 1999. </plain></SENT>
<SENT sid="605" pm="."><plain>Augmentation of the CD8+ T cell response by IFN-gamma in IL-12-deficient mice during Toxoplasma gondii infection. J. </plain></SENT>
<SENT sid="606" pm="."><plain>Immunol. 162:5449–5454. <?supplied-pmid 10228024?>10228024 </plain></SENT>
</text></ref><ref id="bib43"><text><SENT sid="607" pm="."><plain>43Mattner, F., J. </plain></SENT>
<SENT sid="608" pm="."><plain>Magram, J. </plain></SENT>
<SENT sid="609" pm="."><plain>Ferrante, P. </plain></SENT>
<SENT sid="610" pm="."><plain>Launois, K. </plain></SENT>
<SENT sid="611" pm="."><plain>Di Padova, R. </plain></SENT>
<SENT sid="612" pm="."><plain>Behin, M.K. </plain></SENT>
<SENT sid="613" pm="."><plain>Gately, J.A. </plain></SENT>
<SENT sid="614" pm="."><plain>Louis, and G. </plain></SENT>
<SENT sid="615" pm="."><plain>Alber. 1996. </plain></SENT>
<SENT sid="616" pm="."><plain>Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur. </plain></SENT>
<SENT sid="617" pm="."><plain>J. </plain></SENT>
<SENT sid="618" pm="."><plain>Immunol. 26:1553–1559. <?supplied-pmid 8766560?>8766560 </plain></SENT>
</text></ref><ref id="bib44"><text><SENT sid="619" pm="."><plain>44Mattner, F., K. </plain></SENT>
<SENT sid="620" pm="."><plain>Di Padova, and G. </plain></SENT>
<SENT sid="621" pm="."><plain>Alber. 1997. </plain></SENT>
<SENT sid="622" pm="."><plain>Interleukin-12 is indispensable for protective immunity against Leishmania major. Infect. </plain></SENT>
<SENT sid="623" pm="."><plain>Immun. 65:4378–4383. <?supplied-pmid 9353008?>9353008 </plain></SENT>
</text></ref><ref id="bib45"><text><SENT sid="624" pm="."><plain>45Mencacci, A., E. </plain></SENT>
<SENT sid="625" pm="."><plain>Cenci, G. </plain></SENT>
<SENT sid="626" pm="."><plain>Del Sero, C. </plain></SENT>
<SENT sid="627" pm="."><plain>Fe d'Ostiani, P. </plain></SENT>
<SENT sid="628" pm="."><plain>Mosci, G. </plain></SENT>
<SENT sid="629" pm="."><plain>Trinchieri, L. </plain></SENT>
<SENT sid="630" pm="."><plain>Adorini, and L. </plain></SENT>
<SENT sid="631" pm="."><plain>Romani. 1998. </plain></SENT>
<SENT sid="632" pm="."><plain>IL-10 is required for development of protective Th1 responses in IL-12-deficient mice upon Candida albicans infection. J. </plain></SENT>
<SENT sid="633" pm="."><plain>Immunol. 161:6228–6237. <?supplied-pmid 9834110?>9834110 </plain></SENT>
</text></ref><ref id="bib46"><text><SENT sid="634" pm="."><plain>46Decken, K., G. </plain></SENT>
<SENT sid="635" pm="."><plain>Kohler, K. </plain></SENT>
<SENT sid="636" pm="."><plain>Palmer-Lehmann, A. </plain></SENT>
<SENT sid="637" pm="."><plain>Wunderlin, F. </plain></SENT>
<SENT sid="638" pm="."><plain>Mattner, J. </plain></SENT>
<SENT sid="639" pm="."><plain>Magram, M.K. </plain></SENT>
<SENT sid="640" pm="."><plain>Gately, and G. </plain></SENT>
<SENT sid="641" pm="."><plain>Alber. 1998. </plain></SENT>
<SENT sid="642" pm="."><plain>Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect. </plain></SENT>
<SENT sid="643" pm="."><plain>Immun. 66:4994–5000. <?supplied-pmid 9746609?>9746609 </plain></SENT>
</text></ref><ref id="bib47"><text><SENT sid="644" pm="."><plain>47Kawakami, K., Y. </plain></SENT>
<SENT sid="645" pm="."><plain>Koguchi, M.H. </plain></SENT>
<SENT sid="646" pm="."><plain>Qureshi, A. </plain></SENT>
<SENT sid="647" pm="."><plain>Miyazato, S. </plain></SENT>
<SENT sid="648" pm="."><plain>Yara, Y. </plain></SENT>
<SENT sid="649" pm="."><plain>Kinjo, Y. </plain></SENT>
<SENT sid="650" pm="."><plain>Iwakura, K. </plain></SENT>
<SENT sid="651" pm="."><plain>Takeda, S. </plain></SENT>
<SENT sid="652" pm="."><plain>Akira, M. </plain></SENT>
<SENT sid="653" pm="."><plain>Kurimoto, and A. </plain></SENT>
<SENT sid="654" pm="."><plain>Saito. 2000. </plain></SENT>
<SENT sid="655" pm="."><plain>IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFN-gamma production by NK cells. J. </plain></SENT>
<SENT sid="656" pm="."><plain>Immunol. 165:941–947. <?supplied-pmid 10878369?>10878369 </plain></SENT>
</text></ref><ref id="bib48"><text><SENT sid="657" pm="."><plain>48Harandi, A.M., B. </plain></SENT>
<SENT sid="658" pm="."><plain>Svennerholm, J. </plain></SENT>
<SENT sid="659" pm="."><plain>Holmgren, and K. </plain></SENT>
<SENT sid="660" pm="."><plain>Eriksson. 2001. </plain></SENT>
<SENT sid="661" pm="."><plain>Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity. J. </plain></SENT>
<SENT sid="662" pm="."><plain>Virol. 75:6705–6709. <?supplied-pmid 11413339?>11413339 </plain></SENT>
</text></ref><ref id="bib49"><text><SENT sid="663" pm="."><plain>49Carr, J.A., J.A. </plain></SENT>
<SENT sid="664" pm="."><plain>Rogerson, M.J. </plain></SENT>
<SENT sid="665" pm="."><plain>Mulqueen, N.A. </plain></SENT>
<SENT sid="666" pm="."><plain>Roberts, and A.A. </plain></SENT>
<SENT sid="667" pm="."><plain>Nash. 1999. </plain></SENT>
<SENT sid="668" pm="."><plain>The role of endogenous interleukin-12 in resistance to murine cytomegalovirus (MCMV) infection and a novel action for endogenous IL-12 p40. J. </plain></SENT>
<SENT sid="669" pm="."><plain>Interferon Cytokine Res. 19:1145–1152. <?supplied-pmid 10547154?>10547154 </plain></SENT>
</text></ref><ref id="bib50"><text><SENT sid="670" pm="."><plain>50Walter, M.J., N. </plain></SENT>
<SENT sid="671" pm="."><plain>Kajiwara, P. </plain></SENT>
<SENT sid="672" pm="."><plain>Karanja, M. </plain></SENT>
<SENT sid="673" pm="."><plain>Castro, and M.J. </plain></SENT>
<SENT sid="674" pm="."><plain>Holtzman. 2001. </plain></SENT>
<SENT sid="675" pm="."><plain>Interleukin 12 p40 production by barrier epithelial cells during airway inflammation. J. </plain></SENT>
<SENT sid="676" pm="."><plain>Exp. </plain></SENT>
<SENT sid="677" pm="."><plain>Med. 193:339–351. <?supplied-pmid 11157054?>11157054 </plain></SENT>
</text></ref><ref id="bib51"><text><SENT sid="678" pm="."><plain>51Xing, Z., A. </plain></SENT>
<SENT sid="679" pm="."><plain>Zganiacz, J. </plain></SENT>
<SENT sid="680" pm="."><plain>Wang, M. </plain></SENT>
<SENT sid="681" pm="."><plain>Divangahi, and F. </plain></SENT>
<SENT sid="682" pm="."><plain>Nawaz. 2000. </plain></SENT>
<SENT sid="683" pm="."><plain>IL-12-independent Th1-type immune responses to respiratory viral infection: requirement of IL-18 for IFN-gamma release in the lung but not for the differentiation of viral-reactive Th1-type lymphocytes. J. </plain></SENT>
<SENT sid="684" pm="."><plain>Immunol. 164:2575–2584. <?supplied-pmid 10679096?>10679096 </plain></SENT>
</text></ref><ref id="bib52"><text><SENT sid="685" pm="."><plain>52den Dunnen, J.T., and S.E. </plain></SENT>
<SENT sid="686" pm="."><plain>Antonarakis. 2001. </plain></SENT>
<SENT sid="687" pm="."><plain>Nomenclature for the description of human sequence variations. Hum. </plain></SENT>
<SENT sid="688" pm="."><plain>Genet. 109:121–124. <?supplied-pmid 11479744?>11479744 </plain></SENT>
</text></ref><ref id="bib53"><text><SENT sid="689" pm="."><plain>53Jeppsson, O., B. </plain></SENT>
<SENT sid="690" pm="."><plain>Petrini, J. </plain></SENT>
<SENT sid="691" pm="."><plain>Andersson, N. </plain></SENT>
<SENT sid="692" pm="."><plain>Heurlin, and G. </plain></SENT>
<SENT sid="693" pm="."><plain>Malm. 1988 Defective handling of mycobacteria. Lancet. 2:570. </plain></SENT>
</text></ref><ref id="bib54"><text><SENT sid="694" pm="."><plain>54Tuerlinckx, D., C. </plain></SENT>
<SENT sid="695" pm="."><plain>Vermylen, B. </plain></SENT>
<SENT sid="696" pm="."><plain>Brichard, J. </plain></SENT>
<SENT sid="697" pm="."><plain>Ninane, and G. </plain></SENT>
<SENT sid="698" pm="."><plain>Cornu. 1997. </plain></SENT>
<SENT sid="699" pm="."><plain>Disseminated Mycobacterium avium infection in a child with decreased tumour necrosis factor production. Eur. </plain></SENT>
<SENT sid="700" pm="."><plain>J. </plain></SENT>
<SENT sid="701" pm="."><plain>Pediatr. 156:204–206. <?supplied-pmid 9083760?>9083760 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
